‘Mitotherapy’ for heart failure

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Sanchís-Gomar, Fabián
dc.contributor.author Lippi, Giuseppe
dc.contributor.author Lucía Mulas, Alejandro
dc.date.accessioned 2016-05-19T08:10:45Z
dc.date.available 2016-05-19T08:10:45Z
dc.date.issued 2016
dc.identifier.citation Sanchis-Gomar, F., Lippi, G., & Lucia, A. (2016). ‘Mitotherapy’ for heart failure. Trends in molecular medicine, 22(4), 267-269. spa
dc.identifier.issn 14714914
dc.identifier.issn 1471499X
dc.identifier.uri http://hdl.handle.net/11268/5149
dc.description.abstract Abnormalities in mitochondrial dynamics along with those for the molecular mediators involved are presently being viewed with increased interest in the field of cardiovascular disease. Recent research highlights OPA1, a dynamin-like GTPase mediating mitochondrial fusion, as well as the 'mitoproteases' OMA1 and YME1L, as potential therapeutic targets against heart failure. spa
dc.description.sponsorship SIN FINANCIACIÓN spa
dc.language.iso eng spa
dc.title ‘Mitotherapy’ for heart failure spa
dc.type article spa
dc.description.impact 10.732 JCR (2016) Q1, 12/290 Biochemistry and Molecular Biology, 14/190 Cell Biology, 6/128 Medicine, Research and Experimental spa
dc.identifier.doi 10.1016/j.molmed.2016.02.007
dc.rights.accessRights openAccess spa
dc.subject.uem Corazón spa
dc.subject.uem Envejecimiento spa
dc.subject.unesco Enfermedad cardiovascular spa
dc.subject.unesco Envejecimiento spa
dc.description.filiation UEM spa
dc.peerreviewed Si spa

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record